期刊文献+

非肌层浸润性混合级膀胱尿路上皮癌组织学特点及预后分析 被引量:5

Characteristics and clinical significance of mixed grade nonmuscle invasive urothelial carcinoma of urinary bladder
原文传递
导出
摘要 目的尽管大部分尿路上皮癌的病理结果表现为单纯的低或高级别类型,但是临床上仍有部分肿瘤表现为高低级别混合型尿路上皮癌。非肌层浸润性混合级别膀胱尿路上皮癌(bladder urothelial carcinoma,BUC)的组织学特点与预后的关系仍不明确。本研究分析非肌层浸润性混合级别BUC组织学构成特点,探讨肿瘤的异质性与患者预后的关系,为更好地了解BUC组织成分的异质性提供理论依据。方法回顾性分析2003-01-07-2015-12-26大连医科大学附属大连市友谊医院437例因非肌层浸润性BUC行经尿道膀胱肿瘤电切术后卡介苗灌注治疗患者的病例资料。选取33例高级别BUC患者作为对照(低级别BUC患者作为阴性对照),判断混合级别BUC组织学构成与临床特点的关系。结果混合级别BUC中低级别成分为主要成分,高级别成分<10%。混合级别组5年肿瘤无进展生存率为93.94%,明显低于高级别组的69.91%,P=0.008;但是与低级别组相似,P=0.087。混合级别组(93.94%)与高级别组(79.65%)5年疾病特异性生存率差异有统计学意义,P<0.001;而与低级别组相似,P=0.152。5年无复发生存率差异无统计学意义,P=0.217。结论高低级别混合性BUC具有独特的临床特点,对BUC临床病理学分级具有良好的指导意义。 OBJECTIVE Although most of the pathological urothelial carcinoma show pure low grade(LG)or high grade(HG)histology,but there are still some clinical features of tumors of high and low grade mixed(MG)urothelial carcinoma.The relationship between pathological feature and prognosis of MG tumors in patients with non muscle invasive urothelial carcinoma is not clear.This study aimed to analyze non muscle invasive bladder urothelial carcinoma(BUC)mixed level histological characteristics and to explore the relationship between tumor heterogeneity and the prognosis of patients,in order to understand the heterogeneity of BUC and provide a theoretical basis for the composition.METHODS The clinical data of 437 cases with a mean age of 66.3 years underwent transurethral resection(TURBT)of nonmuscle invasive bladder tumors by intravesical Bacillus Calmette-Guérin(BCG)therapy were analyzed retrospectivly.There were 341 males and 96 females.We selected 33 cases of high grade bladder cancer patients as control,and determined relationship between the mixture grade bladder cancer histological structure and clinical characteristics.RESULTS The specimen with MG BUC showed less than 10% HG element.Five-year progression-free survival in patients with high grade tumors was obviously lower to mixed grade(69.91%vs 93.94%,P=0.008),but similar to low grade(P=0.087).Five-year disease specific survival was significantly lower for high grade tumors(79.65%vs 93.94%,P〈0.001),but similar to low grade(P=0.152).CONCLUSION Mixed high and low grade BUC represents unique clinical characteristics,the clinical pathology classification of bladder cancer has a good guiding significance.
作者 魏伟 杨明州 刘天卿 王海波 姜兴金 刘建光 杨进益 WEI Wei;YANG Ming-zhou;LIU Tian-qing;WANG Hai-bo;JIANG Xing-jin;LIU Jian-guang;YANG Jin-yi(Affiliated Dalian Friendship Hospital of Dalian Medical University, Dalian 116001, P. R. China)
出处 《中华肿瘤防治杂志》 CAS 北大核心 2018年第11期812-815,820,共5页 Chinese Journal of Cancer Prevention and Treatment
关键词 膀胱肿瘤 上皮 病理分级 死亡率 bladder neoplasms urothelium cancer pathology grade mortality
  • 相关文献

参考文献2

二级参考文献27

  • 1温机灵,周祥福,高新,黄文涛,张涛,蔡育彬,邱剑光,苏祖兰.膀胱癌术前活检分级低估现象分析[J].中华泌尿外科杂志,2006,27(12):833-835. 被引量:17
  • 2黄鲑,林天歆,李锴文,等.中㈤膀胱癌诊断和治疗现状凋杏及初步分析[J].中肀泌诚外科杂忐,2014,35:8-9.
  • 3Orlinger M ,Catto JH ,()nitoft TF,et al. InJratumour lH*tt*n)gen<*ityin urologic cancers : fnmi molecular evidence to clinicalimplications f J]. Eur Urol,2015 ,67 :729-737.
  • 4Cancer Genome Atlas Kt^earch Network. Comprehensivemolecular characterization of urothelial bladder carcinonu* [J].Nalure,2014, 507:315-322.
  • 5Choi W’Porten S, Kim S,et al. Identification of distinct hasal andluminal subtypes of muscle-invasive Madder cancer willi (Hffereiilsensitivities to frontline cheTnotherapy [ J ] . Cancer Cell, 2014 ,25:152-165.
  • 6Knowles MA,Hurst CD. Molecular biology of bladder cancer:newinsights into pathogenesis and clinical diversity [ J ]. Nat RevCancer,2015,15 :25-41.
  • 7Sakano S,Ogawa S,Yamamoto Y, et al. ERCC1 and XRCC1expression predicts survival in bladder cancer patients receivingcombined trimodality therapy [ J]. Mol Clin Oncol,2013,1:403-410.
  • 8Li S,Wu J, Chen Y, et al. ERCC1 expression levels predict theoutcome of platinum-based chemotherapies in advanced bladdercancer : a meta-analysis [J]. Anticancer Drugs, 2014, 25 : 106-114.
  • 9Van Allen EM, Mouw KW, Kim P, et al. Somatic ERCC2mutations correlate with cisplatin sensitivity in muscle-invasiveurothelial carcinoma [J]. Cancer Discov,2014,4: 1140-1153.
  • 10Groenendijk FH, de Jong J, Fransen van de Putte EE, et al.ERBB2 mutations characterize a subgroup of muscle-invasivebladder cancers with excellent response to neoadjuvantchemotherapy [ J]. Eur Urol,2015 Jan 14[2015-05-26]. http://www. ncbi. nlm. nih. gov/pubmed/25636205. [ published onlineahead of print January 14,2015].

共引文献33

同被引文献51

引证文献5

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部